Wednesday, September 03, 2008

Sanofi Aventis - Multaq: now for the good news

MUNICH, Sept 3 (Reuters) - Sanofi-Aventis's experimental heart drug Multaq (dronedarone) decreases the risk of stroke by more than a third in patients with atrial fibrillation researchers said on Wednesday at the European Society of Cardiology meeting.

More from Ben Hirschler

In 2006 the FDA rejected Multaq , evidently unsatisfied with the data provided at that time to support its application. The company refiled and won a priority review last month.

Ahh! Those wasted patent years!

No comments: